NCT02657447View on ClinicalTrials.gov

Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

December 19, 2017

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2020

Conditions
Non-Hodgkin Lymphoma
Interventions
DRUG

Betalutin with lilotomab dose 1

15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1

DRUG

Betalutin with lilotomab dose 2

15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2

Trial Locations (1)

Unknown

Universitätsklinikum Würzburg, Würzburg

Sponsors

Lead Sponsor

Nordic Nanovector
All Listed Sponsors
lead

Nordic Nanovector

INDUSTRY

NCT02657447 - Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02) | Biotech Hunter | Biotech Hunter